CA3088661A1 - Methods for treating diabetes, hepatitis, and/or inflammatory liver disease - Google Patents

Methods for treating diabetes, hepatitis, and/or inflammatory liver disease Download PDF

Info

Publication number
CA3088661A1
CA3088661A1 CA3088661A CA3088661A CA3088661A1 CA 3088661 A1 CA3088661 A1 CA 3088661A1 CA 3088661 A CA3088661 A CA 3088661A CA 3088661 A CA3088661 A CA 3088661A CA 3088661 A1 CA3088661 A1 CA 3088661A1
Authority
CA
Canada
Prior art keywords
diabetes
subject
antibody
limited
pancreatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3088661A
Other languages
English (en)
French (fr)
Inventor
Michael A. Lynes
Yu-Hua Tseng
Matthew D. LYNES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Joslin Diabetes Center Inc
Original Assignee
University of Connecticut
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut, Joslin Diabetes Center Inc filed Critical University of Connecticut
Publication of CA3088661A1 publication Critical patent/CA3088661A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3088661A 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease Pending CA3088661A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
US62/618,332 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
CA3088661A1 true CA3088661A1 (en) 2019-07-25

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3088661A Pending CA3088661A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Country Status (20)

Country Link
US (3) US11866488B2 (enExample)
EP (2) EP3740282B1 (enExample)
JP (2) JP7486423B2 (enExample)
KR (1) KR20200110659A (enExample)
CN (2) CN120267797A (enExample)
AU (2) AU2019209491B2 (enExample)
BR (1) BR112020014346A2 (enExample)
CA (1) CA3088661A1 (enExample)
EA (1) EA202091533A1 (enExample)
ES (1) ES3033317T3 (enExample)
HR (1) HRP20250727T1 (enExample)
HU (1) HUE072418T2 (enExample)
IL (2) IL276097B2 (enExample)
MX (1) MX2020007384A (enExample)
PH (1) PH12020551076A1 (enExample)
PL (1) PL3740282T3 (enExample)
RS (1) RS66918B1 (enExample)
SG (1) SG11202006421RA (enExample)
SM (1) SMT202500233T1 (enExample)
WO (1) WO2019143767A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
AU2020315367A1 (en) 2019-07-15 2022-02-03 University Of Connecticut Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
WO2007012188A1 (en) 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
CN102725312B (zh) * 2009-10-20 2014-10-01 佐治亚州立大学研究基金会公司 用于糖尿病治疗和β细胞成像的蛋白药物
EP2627638B1 (en) 2010-10-14 2017-07-12 Immunahr AB 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
CA2840282C (en) * 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
US10695406B2 (en) * 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos

Also Published As

Publication number Publication date
EP3740282C0 (en) 2025-03-26
CN111801140B (zh) 2025-05-16
WO2019143767A1 (en) 2019-07-25
IL316486A (en) 2024-12-01
EP3740282B1 (en) 2025-03-26
US20240025981A1 (en) 2024-01-25
EP4596042A3 (en) 2025-11-05
KR20200110659A (ko) 2020-09-24
AU2022215285A1 (en) 2022-09-29
JP2021511296A (ja) 2021-05-06
AU2019209491A1 (en) 2020-07-23
JP2024028454A (ja) 2024-03-04
IL276097A (en) 2020-08-31
EP4596042A2 (en) 2025-08-06
JP7486423B2 (ja) 2024-05-17
EP3740282A1 (en) 2020-11-25
IL276097B2 (en) 2025-04-01
CN111801140A (zh) 2020-10-20
AU2022215285B2 (en) 2024-08-29
PH12020551076A1 (en) 2021-08-16
AU2019209491B2 (en) 2022-05-19
PL3740282T3 (pl) 2025-07-21
IL276097B1 (en) 2024-12-01
US20200369757A1 (en) 2020-11-26
EA202091533A1 (ru) 2020-11-16
ES3033317T3 (en) 2025-08-01
HUE072418T2 (hu) 2025-11-28
US20240067710A1 (en) 2024-02-29
CN120267797A (zh) 2025-07-08
RS66918B1 (sr) 2025-07-31
SMT202500233T1 (it) 2025-07-22
US11866488B2 (en) 2024-01-09
BR112020014346A2 (pt) 2020-12-08
SG11202006421RA (en) 2020-08-28
MX2020007384A (es) 2020-10-19
HRP20250727T1 (hr) 2025-10-24

Similar Documents

Publication Publication Date Title
AU2022215285B2 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
CN111939261B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
JP6633108B2 (ja) 脂肪組織の集積を処置するための組成物および方法
JP6373944B2 (ja) Ｉｌ−２１抗体
CN102548573B (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
JP2021515039A (ja) 重症喘息を処置するための組成物および方法
US20120308564A1 (en) Treatment of a metabolic disorder
KR20250016223A (ko) 항인슐린 수용체 항체를 위한 제형 및 이의 용도
HK40040177B (en) Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease
HK40040177A (en) Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease
EA048509B1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809

EEER Examination request

Effective date: 20220809